Relationship between HBsAG and TSH during interferon treatment in hepatitis B patients with low HBsAg level
10.3969/j.issn.1671-8348.2024.18.020
- VernacularTitle:低HBsAg水平乙型肝炎患者使用干扰素治疗期间HBsAg与TSH的关系
- Author:
Huan MU
1
;
Danqing XU
;
Chunyun LIU
;
Li LIU
Author Information
1. 昆明市第三人民医院(云南省传染性疾病临床医学中心)肝病免疫科,昆明 650041
- Keywords:
long acting interferon;
anti viral treatment of hepatitis B;
thyroid stimulating hormone
- From:
Chongqing Medicine
2024;53(18):2826-2829
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between hepatitis B (HB) surface antigen (HB-sAg) and thyroid-stimulating hormone (TSH) during pegylated interferon α-2b (PEG-IFNα-2b) treatment in the HB patients with low HBsAg level.Methods A total of 103 HB patients with low HBsAg level conduc-ting PEG-IFNα-2b combined with nucleos(t)ide analogues antiviral treatment in this hospital during 2020-2022 were selected as the study subjects and divided into the TSH increase group,TSH normal group and TSH decrease group according to the TSH level of the patients during PEG-IFNα-2b treatment.The general data and laboratory indexes in various groups were collected.The differences in HBsAg levels were analyzed. Results There were no statistically significant differences in baseline gender,age,WBC,Hb,PLT,HBsAg,to-tal triiodothyronine (TT3),total thyroxine (TT4),free triiodothyronine (FT3),free thyroxine (FT4) and TSH among the groups (P>0.05).There were statistically significant differences in the level of HBsAg be-tween 24-week treatment and 48-week treatment and the degree of HBsAg decrease at 24-week treatment a-mong the groups (P<0.05).The HBsAg level after 24-week,48-week treatment in the TSH decrease group was significantly lower than that in the normal TSH group,and the decrease degree of HBsAg at 24-week treatment was significantly higher than that in the normal TSH group,and the differences were statistically significant (P<0.05).Conclusion PEG-IFN-α-2b has better antiviral efficacy for TSH decrease(hyperthy-roidism/subclinical hyperthyroidism) in the patients with HBsAg low level hepatitis B.
